IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IRulya Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$34.45+2.42 (+7.56%)
Close on Oct 19, 2026
- Market cap
- $211.28M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$337.55 (−90.74%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $211.28M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -22.25%
Fundamentals
- Net income
- -$92.48M
- EPS, diluted
- -$16.80
- Free cash flow
- -$47.00M
- Book value per share
- -$5.76
- Diluted shares
- 6M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Operating income
-$127.16M
Net income
-$92.48M
EPS, diluted
–
Free cash flow
-$47.00M
Reported periodTrailing twelve months